Payment overview · 2025
General Payments
$1,985.83
21 reported records · 8 companies
Healthcare provider profile · identity verified
Darrell Lee Murray, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ATLANTA, GA · NPI 1447250170
Verified facts
What the public records show
CMS Open Payments records show Darrell Lee Murray, M.D. received $1,985.83 in general payments during 2025 across 21 reported records.
Neurocrine BioSciences, Inc. accounted for 72.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $1,433.46 | 72.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $247.46 | 12.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 6.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $73.51 | 3.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $56.04 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.58 | 1.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.93 | 0.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.85 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,102.29 | 4 |
| Food and Beverage | $883.54 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.46 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $73.51 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $56.04 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 187 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
187 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 487 | 137 |
| Gabapentin | Gabapentin | 353 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 103 |
| Lisinopril | Lisinopril | 263 | 72 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 236 | 31 |
| Metformin Hcl | Metformin Hcl | 226 | 68 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 225 | 26 |
| Ozempic | Semaglutide | 187 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 41 |
| Ibuprofen | Ibuprofen | 117 | 47 |
| Clonidine Hcl | Clonidine Hcl | 114 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 11 |
| Omeprazole | Omeprazole | 109 | 35 |
| Mounjaro | Tirzepatide | 104 | 14 |
| Tramadol Hcl | Tramadol Hcl | 101 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 28 |
| Trazodone Hcl | Trazodone Hcl | 81 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 33 |
| Glipizide | Glipizide | 69 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 19 |
| Losartan Potassium | Losartan Potassium | 63 | 26 |
| Furosemide | Furosemide | 62 | 22 |
| Carvedilol | Carvedilol | 61 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Levetiracetam | Levetiracetam | 53 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 21 |
| Sertraline Hcl | Sertraline Hcl | 52 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 18 |
| Eliquis | Apixaban | 47 | suppressed |
| Famotidine | Famotidine | 47 | 14 |
| Potassium Chloride | Potassium Chloride | 45 | 12 |
| Allopurinol | Allopurinol | 44 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 15 |
| Meloxicam | Meloxicam | 36 | 18 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Risperidone | Risperidone | 34 | 11 |
| Modafinil | Modafinil | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 25 |
| Simvastatin | Simvastatin | 31 | 11 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 27 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Baclofen | Baclofen | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | 15 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Temazepam | Temazepam | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Metronidazole | Metronidazole | 13 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Diazepam | Diazepam | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,985.83 · 21 records | Neurocrine BioSciences, Inc. | BREZTRI, FREESTYLE LIBRE 3, Kerendia, Ozempic, REXULTI, SUBLOCADE, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error